Shanghai Haohai Biological Technology Co Ltd banner

Shanghai Haohai Biological Technology Co Ltd
SSE:688366

Watchlist Manager
Shanghai Haohai Biological Technology Co Ltd Logo
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
Watchlist
Price: 39.54 CNY 1.13% Market Closed
Market Cap: ¥9.1B

P/S

3.6
Current
31%
Cheaper
vs 3-y average of 5.3

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
3.6
=
Market Cap
¥8.8B
/
Revenue
¥2.5B

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
3.6
=
Market Cap
¥8.8B
/
Revenue
¥2.5B

Valuation Scenarios

Shanghai Haohai Biological Technology Co Ltd is trading below its 3-year average

If P/S returns to its 3-Year Average (5.3), the stock would be worth ¥57.54 (46% upside from current price).

Statistics
Positive Scenarios
3/4
Maximum Downside
-24%
Maximum Upside
+240%
Average Upside
96%
Scenario P/S Value Implied Price Upside/Downside
Current Multiple 3.6 ¥39.54
0%
3-Year Average 5.3 ¥57.54
+46%
5-Year Average 8 ¥87.19
+121%
Industry Average 12.3 ¥134.44
+240%
Country Average 2.8 ¥30.22
-24%

Forward P/S
Today’s price vs future revenue

Today's Market Cap Revenue Forward P/S
¥8.8B
/
Jan 2026
¥2.5B
=
3.6
Current
¥8.8B
/
Dec 2026
¥2.9B
=
3
Forward
¥8.8B
/
Dec 2027
¥3.2B
=
2.8
Forward

Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
P/S
P/E
All Countries
Close
Market Cap P/S P/E
CN
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
8.9B CNY 3.6 35.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7
US
Abbvie Inc
NYSE:ABBV
351.3B USD 5.7 83.9
US
Amgen Inc
NASDAQ:AMGN
185.7B USD 5 24.1
US
Gilead Sciences Inc
NASDAQ:GILD
161.8B USD 5.5 19
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
109.3B USD 9.1 27.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.4B USD 5.5 17.6
NL
argenx SE
XBRU:ARGX
41.2B EUR 11.5 37
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8
AU
CSL Ltd
ASX:CSL
62.7B AUD 2.8 31.1
P/E Multiple
Earnings Growth PEG
CN
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
Average P/E: 34.5
35.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
83.9
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.1
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
19
16%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.6
19%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.6
14%
1.3
NL
argenx SE
XBRU:ARGX
37
30%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
AU
CSL Ltd
ASX:CSL
31.1
9%
3.5

Market Distribution

In line with most companies in China
Percentile
58th
Based on 7 736 companies
58th percentile
3.6
Low
0 — 1.5
Typical Range
1.5 — 5.4
High
5.4 —
Distribution Statistics
China
Min 0
30th Percentile 1.5
Median 2.8
70th Percentile 5.4
Max 5 034 353.9

Shanghai Haohai Biological Technology Co Ltd
Glance View

Market Cap
9.1B CNY
Industry
Biotechnology

Shanghai Haohai Biological Technology Co., Ltd. operates at the cutting edge of the biopharmaceutical industry, specializing in regenerative medicine, medical aesthetics, and other biotechnology applications. Founded on the principles of innovation and science-driven solutions, the company has built an impressive portfolio that underscores its expertise in biological materials. Core to its operations is the development and commercialization of hyaluronic acid products, pivotal in fields such as ophthalmology, wound care, and more recently, dermal fillers for aesthetic treatments. Haohai Biological leverages high-end biotechnological processes to produce its offerings, ensuring that they meet the highest standards of quality and efficacy—a strategy that has allowed it to capture significant market share both domestically within China and beyond its borders. The revenue streams of Haohai Biological are as diversified as its product lines. The company generates income primarily through the sale of its high-margin pharmaceutical and medical device products. It has strategically positioned itself in the burgeoning market for medical aesthetics, where demand for cosmetic enhancements is rapidly growing, fueled by a global shift toward non-invasive procedures. Additionally, its ophthalmic products, crucial for surgeries and various ocular conditions, continue to be significant revenue drivers. Beyond product sales, Haohai invests in licensing its technologies and forging strategic partnerships with international firms, further enhancing its market reach and capitalizing on global biotechnology trends. This multifaceted approach positions the company not only as a producer but as a leader in scientific innovation and commercialization in the biotechnology sector.

Intrinsic Value
55.24 CNY
Undervaluation 28%
Intrinsic Value
Price ¥39.54
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett